Seymour Pierce maintains its “sell” recommendation with a target price of 1p for the music and entertainment business, based on fierce market competition and the swift loss of both its chief exec and finance director.
UBS lists the pharma giant as one of its top picks, along with Novartis, and predicts the generics sector will see sales growth of five to six per cent in 2014-15. It sets a target price of 3,600p, with a “buy” rating.
MED OIL AND GAS
Liberum has increased its target price by 9p to 22p, with a “buy” rating, based on Italian Prime Minister Mario Monti’s “growth decree” which means an offshore ban will no longer apply to its licences.